* Entera Bio Ltd ENTX.OQ ENTX.O is expected to show a
fall in
quarterly revenue when it reports results on August 14
(estimated).
*
* Refinitiv's mean analyst estimate for Entera Bio Ltd is
for a
loss of 7 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Entera Bio
Ltd is
$6, above its last closing price of $0.75.
This summary was machine generated August 11 at 17:13 GMT. All
figures in US dollars unless otherwise stated